Exelixis | EXEL - Sales Revenues


Exelixis reported $597.8M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
Agios Pharmaceuticals USD 12.9M 450K Sep/2025
Amgen USD 9.9B 340M Dec/2025
AstraZeneca USD 15.19B 733M Sep/2025
Bayer EUR 9.66B 1.08B Sep/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Cytokinetics USD 1.93M 64.83M Sep/2025
Eisai JPY 197.36B 5.29B Sep/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Exelixis USD 597.8M 29.5M Sep/2025
Genmab DKK 5.86B 580M Jun/2025
Glaxosmithkline GBP 11.52B 3.54B Sep/2025
Incyte USD 1.37B 310M Sep/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
MacroGenics USD 72.84M 50.6M Sep/2025
Merck USD 16.4B 880M Dec/2025
Moderna USD 1.02B 878M Sep/2025
Neurocrine Biosciences USD 794.9M 107.4M Sep/2025
Novartis USD 13.91B 144M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
Sanofi EUR 12.2B 3.19B Dec/2025
Takeda JPY 1.19T 80B Dec/2025
Ultragenyx Pharmaceutical USD 160M 6.5M Sep/2025
Xencor USD 21M 22.61M Sep/2025